Effect of dexmedetomidine on somatosensory- and motor-evoked potentials in patients receiving craniotomy under propofol-sevoflurane combined anesthesia

• Published in: Frontiers in surgery Vol. 11; p. 1386049
• Main Authors: Yang, Xue, Zhang, Xinyi, Lin, Puxuan, Liu, Zeheng, Deng, Shuhang, Liang, Shanwen, Zhu, Xinyi, Qiao, Qianqian, Chen, Qianxue
• Format: Journal Article
• Language: English
• Published: Switzerland Frontiers Media S.A 09.07.2024
• Subjects: dexmedetomidine; intraoperative neurophysiological monitoring; neurosurgery; prognosis; Surgery; transcranial motor-evoked potentials; transcranial motor-evoked potentials; dexmedetomidine; intraoperative neurophysiological monitoring; neurosurgery; prognosis
• ISSN: 2296-875X; 2296-875X
• DOI: 10.3389/fsurg.2024.1386049

Dexmedetomidine is often used as an adjunct to total intravenous anesthesia (TIVA) for procedures requiring intraoperative neurophysiologic monitoring (IONM). However, it has been reported that dexmedetomidine might mask the warning of a neurological deficit on intraoperative monitoring. We reviewed the intraoperative neurophysiological monitoring data of 47 patients who underwent surgery and IONM from March 2019 to March 2021 at the Department of Neurosurgery, Renmin Hospital of Wuhan University. Pre- and postoperative motor function scores were recorded and analyzed. Dexmedetomidine was administered intravenously at 0.5 μg/kg/h 40 min after anesthesia and discontinued after 1 h in the dexmedetomidine group. We found that the amplitude of transcranial motor-evoked potentials (Tce-MEPs) was significantly lower in the dexmedetomidine group than in the negative control group (  < 0.0001). There was no statistically significant difference in the somatosensory-evoked potentials (SSEPs) amplitude or the Tce-MEPs or SSEPs latency. There was no significant decrease in postoperative motor function in the dexmedetomidine group compared with the preoperative group, suggesting that there is no evidence that dexmedetomidine affects patient prognosis. In addition, we noticed a synchronized bilateral decrease in the Tce-MEPs amplitude in the dexmedetomidine group and a mostly unilateral decrease on the side of the brain injury in the positive control group (  = 0.001). Although dexmedetomidine does not affect the prognosis of patients undergoing craniotomy, the potential risks and benefits of applying it as an adjunctive medication during craniotomy should be carefully evaluated. When dexmedetomidine is administered, Tce-MEPs should be monitored. When a decrease in the Tce-MEPs amplitude is detected, the cause of the decrease in the MEPs amplitude can be indirectly determined by whether the decrease is bilateral.